Company Overview and News

10
Vitamin Shoppe: Cognitive Dissonance And Why We Got Short When Shares Crossed $11

2018-08-11 seekingalpha
Vitamin Shoppe's stock is on a tear after posting better than feared Q2 2018 results, but this just feels like a short squeeze.
GNC VSI MS

60
Time to Take Profits in Vitamin Shoppe Stock

2018-08-11 investorplace
After a dismal 2017, retailers have mostly rallied in 2018, and Vitamin Shoppe (NYSE:VSI) has been one of the biggest winners. VSI stock has gained over 150% just since early April. An activist effort, two straight quarters of “good enough” earnings, and likely some short-covering have driven the rally.
GS AMZN AEO VSI GNC ANF URBN

21
Goldman Puts Money Behind Vitamin Startup Valued Close to GNC - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK GSC TFG GNC GSJ BRK.A GS GLSSP AAPL VSI GJS

1
Is GNC Holdings (GNC) a Great Stock for Value Investors?

2018-08-07 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
GNC

121
7 High Short-Interest Stocks

2018-08-06 investorplace
Short selling seems unsavory. It is betting that a company’s stock will drop, after all. However, many of the world’s top investors engage in this activity — George Soros, Paul Tudor Jones and John Paulson just to name a few. Short positions are required to be disclosed to the public. This is what gives us short interest. High-short interest stocks are stocks with a higher than usual amount of short interest.
APRN ENT GNC ENTWW VZA SHLD VSAT KR AMZN FTRPR GRUB TSLA VZ GOGO FTR

0
GNC / GNC Holdings, Inc. 8-K (Current Report)

2018-08-03 sec.gov
Document UNITED STATES
GNC

11
GNC Holdings: Bring A Knife To A Gun Fight

2018-07-30 seekingalpha
On July 26, 2017, GNC beat Q2 2018 Adjusted EBITDA estimates by 18%, yet its stock barely moved that day.
VSI GNC MS

1
BJ's Restaurants (BJRI) Q2 Earnings, Revenues Top Estimates

2018-07-27 zacks
BJ’s Restaurants, Inc.’s (BJRI - Free Report) top and bottom lines both surpassed the Zacks Consensus Estimate in the second quarter of 2018. Adjusted earnings of 79 cents surpassed the consensus estimate of 64 cents by 23.4%. Earnings surged 61.2% year over year favored by improved comps and restaurant operating margins.
BJRI GNC XL FRSH XLGLF DENN TAST

3
Republic Services (RSG) Q2 Earnings In Line, Revenues Lag

2018-07-27 zacks
Republic Services, Inc. (RSG - Free Report) reported mixed second-quarter 2018 results, with earnings in line with the Zacks Consensus Estimate and revenues missing the same.
RSG GNC XL BKFS XLGLF FIS BKI CLH

0
Iron Mountain's (IRM) Q2 FFO & Revenues Beat, Improve Y/Y

2018-07-27 zacks
Iron Mountain Inc. (IRM - Free Report) reported second-quarter 2018 normalized funds from operations (FFO) of 56 cents per share, beating the Zacks Consensus Estimate of 53 cents. The reported figure inched up 1.8% year over year. Results reflect decent storage rental revenue and margin expansion. Adjusted FFO increased 5.8% year over year to $230 million. Quarter Details Revenues of $1.06 billion beat the Zacks Consensus Estimate of $1.
ARE GNC XL SPG XLGLF AVB

1
Chevron (CVX) Sets $3B Buyback Plan Even as Q2 Earnings Miss

2018-07-27 zacks
Chevron Corporation (CVX - Free Report) reported weaker-than-expected second-quarter earnings, pressured by drop in profits in its downstream business, which refines crude oil into fuels like gasoline and diesel oil. The U.S. energy major reported earnings per share of $1.78, lagging the Zacks Consensus Estimate of $2.06.
RDS.B RDS.A CVX GNC RYDBF XL XLGLF RDSB RDSA RYDAF

0
Goodyear (GT) Beats on Q2 Earnings, Misses Sales, Lowers View

2018-07-27 zacks
The Goodyear Tire & Rubber Company (GT - Free Report) reported adjusted earnings per share of 62 cents, down from 70 cents in the prior-year quarter. The bottom line surpassed the Zack Consensus Estimate of 56 cents. The company reported net income of $157 million, up from $147 million in the year-ago quarter. The company delivered net revenues of $3.84 billion, higher than $3.70 billion in the year-ago quarter.
FOXF OSK GNC XL XLGLF

1
Rockwell Collins (COL) Q3 Earnings Miss, Revenues Up Y/Y

2018-07-27 zacks
Rockwell Collins Inc. (COL - Free Report) reported financial results for third-quarter fiscal 2018 (ended Jun 30, 2018). The company’s adjusted earnings per share of $1.73 lagged the Zacks Consensus Estimate of $1.89 by 8.5%. Reported earnings, however, grew 5.5% from $1.64 per share a year ago. Excluding the one-time items, the company reported GAAP earnings per share of $1.66 in the reported quarter, which increased 48.
LMT HXL HXL GNC XL XLGLF COL TXT

9
Twitter Meets Earnings Expectations but the Shares Get Punished

2018-07-27 zacks
Shares in Twitter (TWTR - Free Report) traded down almost 20% on Friday after the company reported quarterly earnings that were in line with projections and beat the consensus estimate for revenues.
FB TWTR GNC XL NFLX XLGLF

3
ExxonMobil (XOM) Earnings Miss Estimates in Q2, Rise Y/Y

2018-07-27 zacks
Exxon Mobil Corporation’s (XOM - Free Report) second-quarter 2018 earnings missed estimates, thanks to a plunge in oil equivalent production. The rise in energy and feedstock cost and significant maintenance and turnaround work hurt the bottom line. This was partially offset by increased price realizations from liquids.
XOM CVX GNC MDR MUR.WI XL MUR XLGLF MCDFF

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 36191G107